5d ; Supplementary Data S4 ), suggesting that these biomarkers may have limitations in detecting patients with severe methylation maintenance loss, such as ASCL2 in LIHC, UNXC in LUSC, and SEPT9 in READ (FDA approved, marginally significant) ( Fig. 5e ).
← all excerpts
Simulation-guided pan-cancer analysis identifies a novel regulator of CpG island hypermethylation heterogeneity.
1
—
—